The AKT3 signalling pathway is constitutively active in ~70% of advanced-stage melanomas and components of this pathway represent potential therapeutic targets because it plays a pivotal role in melanoma progression by, in part, repressing the cell adhesion molecule E-cadherin [17, 29]. Here, AKT3 is linked to melanoma.